Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN64,7264,783,51
Msft-0,59
Nokia4,50054,6195-0,86
IBM0,21
Mercedes-Benz Group AG62,4462,461,67
PFE-0,16
30.11.2022 0:38:20
Indexy online
AD Index online
select
AD Index online
 

  • 29.11.2022 17:35:23
Guerbet SA (GRBT.PA, Paris)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
16,86 0,84 0,14 111 710
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 30.11.2022
Popis společnosti
Obecné informace
Název společnostiGuerbet SA
TickerGBT
Kmenové akcie:Ordinary Shares
RICGRBT.PA
ISINFR0000032526
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.09.2022
Počet zaměstnanců k 31.12.2021 2 730
Akcie v oběhu k 30.06.2022 12 625 395
MěnaEUR
Kontaktní informace
Ulice15 rue des Vanesses, Zone Paris Nord II
MěstoVILLEPINTE
PSČ93420
ZeměFrance
Kontatní osoba 
Funkce kontaktní osoby 
Telefon33 145 915 000
Fax33145915199

Business Summary: Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The Company operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.
Financial Summary: BRIEF: For the six months ended 30 June 2022, Guerbet SA revenues increased 2% to EUR371.1M. Net income applicable to common stockholders decreased 86% to EUR3.3M. Revenues reflect World excl. Europe segment increase of 9% to EUR206.5M. Net income was offset by External charges increase of 18% to EUR104.1M (expense), Staff-related costs increase of 3% to EUR121.4M (expense).
Odvětvová klasifikace
TRBC2012Medical Imaging Systems
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations



  • Poslední aktualizace: 30.11.2022
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Member of the Executive CommitteeDavid Hale5301.01.2020
Deputy Chief Executive Officer, Chief Pharmacist, Senior Vice President of Development, Medical & Regulatory Affairs, Member of Philippe Bourrinet5324.03.2021
Chief Financial Officer, Senior Vice President - Business Development and Licensing, Member of the Executive CommitteeJerome Estampes-01.01.2019
Senior Vice President - Human Resources and Corporate Social Responsibility, Member of the Executive CommitteePetra Zalabak-01.01.2020
Senior Vice President - Interventional Imagin, Member of the Executive CommitteeJean-Francois Blanc-
Senior Vice President - Diagnostic Imaging, Member of the Executive CommitteeValerie Brissart-
Senior Vice President - Technical Operations, Interim Chief Pharmacist, Member of the Executive CommitteeSarah Dayre-01.02.202101.02.2021
Senior Vice President - Commercial Operations Asia-Pacific, Member of the Executive CommitteeMathieu Elie-
Senior Vice President - Commercial Operations, Americas and EMEA, Member of the Executive CommitteeGitte Hesselholt-
Senior Vice President - R&D and R&I, Chief Digital Officer, Member of the Executive CommitteeFrancois Nicolas-